2023 World Conference on Lung Cancer (Posters)-EP10.01. Patterns of Systemic Anti-Cancer Therapy & Overall Survival of Stage IV NSCLC at Tertiary General Hospital

EP10.01. Patterns of Systemic Anti-Cancer Therapy & Overall Survival of Stage IV NSCLC at Tertiary General Hospital - PDF(Abstract)

Back to course

Pdf Summary

This study investigated the clinical characteristics, patterns of anti-cancer therapy, and overall survival of stage IV non-small cell lung cancer (NSCLC) patients at a tertiary hospital in Jakarta, Indonesia. The goal of treating stage IV NSCLC is palliative, aiming to control symptoms, improve quality of life, and prolong survival. The systemic treatment options for stage IV NSCLC include chemotherapy, targeted therapy, and immunotherapy. However, at the study hospital, immunotherapy is not covered by government insurance.<br /><br />The study included 97 patients with metastatic NSCLC between January 2014 and December 2019. The most common subtype of NSCLC was adenocarcinoma. The most common comorbidities among the patients were pneumonia, hypertension, coronary heart disease, and diabetes mellitus. The patterns of available systemic treatment were analyzed, and the most common first-line chemotherapy regimen for patients without a driver mutation was platinum-taxanes. The most common first-line targeted therapy for patients with an EGFR mutation was Gefitinib.<br /><br />The median survival of patients in the non-treated group versus the treated group was 1 and 12 months, respectively. The median survival of patients in the chemotherapy group versus the targeted therapy group was 11 and 16 months, respectively. The most favorable survival outcomes were observed in the targeted therapy group.<br /><br />In conclusion, the demographic characteristics of metastatic NSCLC patients in this study were similar to those of other studies. The most common systemic therapies used were platinum-taxanes for chemotherapy and Gefitinib for targeted therapy. Pneumonia, hypertension, coronary heart disease, and diabetes mellitus were the most common comorbidities. The targeted therapy group had the most favorable overall survival, followed by the systemic chemotherapy group.

Asset Subtitle

Wulyo Rajabto

Meta Tag

Speaker Wulyo Rajabto

Topic Metastatic NSCLC: Cytotoxic Therapy

Keywords

stage IV non-small cell lung cancer

chemotherapy

targeted therapy

immunotherapy

metastatic NSCLC

pneumonia

hypertension

coronary heart disease

diabetes mellitus

overall survival